Related Experiment Video

Updated: Feb 25, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

The importance for immunoregulation for long-term cancer control

Alberto Fusi1,2, Angus Dalgleish1

  • 1Infection & Immunity Research Center - St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.

Future Oncology (London, England)
|August 5, 2017
PubMed

Insights

Immune checkpoint blockade therapy offers breakthroughs for solid tumors like melanoma. Research focuses on improving patient response, minimizing side effects, and converting non-responders to responders for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) represent a significant advancement in treating solid tumors, including melanoma.
  • Combination therapy with ipilimumab and nivolumab demonstrates high efficacy in melanoma, yet approximately half of patients do not respond.
  • Enhancing the therapeutic ratio and patient outcomes remains a critical challenge in cancer immunotherapy.

Purpose of the Study:

  • To review recent findings in immune checkpoint blockade therapy for solid tumors.
  • To address key research questions regarding maximizing treatment benefits and minimizing toxicity.
  • To explore strategies for identifying likely responders and converting non-responders to immunotherapy.

Main Methods:

  • Literature review of recent advancements in cancer immunotherapy.
  • Analysis of current research trends and challenges in immune checkpoint blockade.
  • Synthesis of findings related to patient selection and treatment optimization.

Main Results:

  • Immune checkpoint blockade therapy has shown high response rates and durability in solid tumors.
  • Combination therapy (ipilimumab/nivolumab) is effective in melanoma but not universally successful.
  • Significant research efforts are directed towards improving patient stratification and overcoming resistance.

Conclusions:

  • Further research is essential to optimize immune checkpoint blockade therapy for broader patient benefit.
  • Developing strategies to identify responders and convert non-responders is crucial for advancing cancer treatment.
  • Future directions include minimizing toxicity and maximizing efficacy in melanoma and other cancers.
Keywords:
NSCLCatezolizumabbiomarkerscheckpoint inhibitorsimmunotherapyipilimumabmelanomanivolumabpembrolizumab

More Related Videos

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
84.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K